Insights

The ASX healthcare shares I would buy and hold until at least 2030

Here’s why I think investors should gain exposure to favourable healthcare trends through investments in ResMed Inc. (ASX:RMD) and…
The post The ASX healthcare shares I would buy and hold until at least 2030 appeared first on Motley Fool Australia. –

Doctor pressing digitised screen with array of icons including one entitled health insurance

Despite the pandemic, over the last 12 months the healthcare sector has been a great place to invest your money.

Since this time last year, the S&P/ASX 200 Health Care index has generated a return of 17%. As a comparison, the benchmark S&P/ASX 200 Index (ASX: XJO) is down 7.2% over the same period.

Due to the growing demand for healthcare services because of ageing populations, improving treatment options, and chronic disease burden, I expect this outperformance to continue over the 2020s.

In light of this, I believe having exposure to the healthcare sector would be a great thing for a portfolio.

But which shares should you buy? Here are two options to consider:

iShares Global Healthcare ETF (ASX: IXJ)

I think the iShares Global Healthcare exchange traded fund (ETF) would be a fantastic option for investors looking for healthcare exposure. Through a single investment, it provides investors with access to a wide range of companies across sectors including biotechnology, pharmaceutical, and medical devices.

Among its holdings you’ll find our very own CSL Limited (ASX: CSL) and Ramsay Health Care Limited (ASX: RHC). And among its many international holdings are the likes of Johnson & Johnson, Pfizer, Novartis, Merck & Co, and United Health. I believe these companies are well-placed for growth over the next decade and feel confident the ETF can generate strong long term returns for investors. 

ResMed Inc. (ASX: RMD)

Another ASX healthcare share I think could provide strong returns for investors over the 2020s is ResMed. It is a medical device company with a focus on sleep treatment products and ventilators. It has been growing at a consistently strong rate over the last decade and looks well-placed to continue this positive form. 

This is due to its world-class, cloud-connected hardware and software solutions and its huge addressable market. Management currently estimates that there are 936 million people with sleep apnoea globally. With the majority of these sufferers undiagnosed, I believe this gives it a significant runway for growth. In addition to this, the company notes that there are 380 million people who suffer from chronic obstructive pulmonary disease (COPD) and over 340 million people living with asthma. These are all people whose lives could be improved with ResMed’s products in the future. 

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The ASX healthcare shares I would buy and hold until at least 2030 appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!